Strong Medicine (eBook)

Creating Incentives for Pharmaceutical Research on Neglected Diseases
eBook Download: EPUB
2016
152 Seiten
Princeton University Press (Verlag)
978-1-4008-8014-0 (ISBN)

Lese- und Medienproben

Strong Medicine - Michael Kremer, Rachel Glennerster
Systemvoraussetzungen
27,99 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
From Nobel Prize-winning economist Michael Kremer and fellow leading development economist Rachel Glennerster, an innovative solution for providing vaccines in poor countriesMillions of people in the third world die from diseases that are rare in the first world-diseases like malaria, tuberculosis, and schistosomiasis. AIDS, which is now usually treated in rich countries, still ravages the world's poor. Vaccines offer the best hope for controlling these diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because governments drive down prices.In Strong Medicine, Michael Kremer and Rachel Glennerster offer an innovative yet simple solution to this worldwide problem: "e;Pull"e; programs to stimulate research. Here's how such programs would work. Funding agencies would commit to purchase viable vaccines if and when they were developed. This would create the incentives for vaccine developers to produce usable products for these neglected diseases. Private firms, rather than funding agencies, would pick which research strategies to pursue. After purchasing the vaccine, funders could distribute it at little or no cost to the afflicted countries.Strong Medicine details just how these legally binding commitments would work. Ultimately, if no vaccines were developed, such a commitment would cost nothing. But if vaccines were developed, the program would save millions of lives and would be among the world's most cost-effective health interventions.

Michael Kremer is Gates Professor of Developing Societies at Harvard University, Senior Fellow at the Brookings Institution, and NonResident Fellow at the Center for Global Development. He founded and was the first executive director of WorldTeach, a nonprofit organization that places two hundred volunteer teachers annually in developing countries (1986-1989). He previously served as a teacher in Kenya. Rachel Glennerster is Director of the Poverty Action Lab at the Massachusetts Institute of Technology, a center devoted to evaluating the effectiveness of anti-poverty programs. She has worked on health and development policy at the UK Treasury, the Harvard Institute of International Development, and the International Monetary Fund.

Erscheint lt. Verlag 31.5.2016
Zusatzinfo 6 line illus. 3 tables.
Verlagsort Princeton
Sprache englisch
Themenwelt Medizin / Pharmazie Gesundheitswesen
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Technik
Wirtschaft Allgemeines / Lexika
Wirtschaft Volkswirtschaftslehre
Schlagworte Adjudication • Advisory Committee on Immunization Practices • Aid • Bill &amp • Bill & Melinda Gates Foundation • Bill Frist • Biotechnology • Bonus payment • bribery • Budget • Buyout • Calculation • clinical trial • Consideration • consumer • Contract • Copayment • cost-effectiveness analysis • Cost of capital • credibility • developed country • Developing Country • diphtheria • Disability-adjusted life year • Disease • disease burden • drug development • efficacy • Expense • Externality • Funding • Government Failure • Haemophilus influenzae • Health Care • health intervention • health policy • Health Technology • hepatitis b vaccine • Hib vaccine • HIV/Aids • HIV vaccine • immunization • Incentive • income • Infant Mortality • Institution • International AIDS Vaccine Initiative • Investment • Investor • Malaria • malaria vaccine • Malnutrition • Management of HIV/AIDS • Manufacturing cost • Marginal cost • Market (economics) • Market Failure • Melinda Gates Foundation • Meningococcal disease • Michael Kremer • Monopoly price • Net Present Value • New Product Development • orphan drug • pathogen • Payment • Pertussis • pharmaceutical drug • Pharmaceutical Industry • Physician • Policy • Poverty • Precedent • Pricing • Private foundation (United States) • private sector • Provision (accounting) • Quantity • regimen • Requirement • Research and Development • salary • Schistosomiasis • Smallpox • Subsidy • Suggestion • Symptom • tax credit • Technology • Tetanus • Tuberculosis • UNICEF • Vaccination • Vaccination schedule • Vaccine • Vaccine trial • Venture Capital • wide variety • Working Group • World Bank • World Health Organization • World Trade Organization
ISBN-10 1-4008-8014-9 / 1400880149
ISBN-13 978-1-4008-8014-0 / 9781400880140
Haben Sie eine Frage zum Produkt?
EPUBEPUB (Adobe DRM)

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich